Summary by Futu AI
Biodexa Pharmaceuticals PLC, a clinical-stage biopharmaceutical company, has filed a prospectus with the SEC for the resale of 1,192,023,200 ordinary shares represented by 2,980,058 American Depositary Shares (ADSs). The selling shareholders identified in the prospectus will be reselling these shares. The ordinary shares include those issued in private placement transactions in December 2023 and shares issuable upon the exercise of pre-funded warrants issued in the same placements. The selling shareholders may sell the shares on the market or in private transactions at fixed or negotiated prices using various methods including block trades or through broker-dealers. Biodexa Pharmaceuticals will not receive any proceeds from the sale of the shares by the selling shareholders. However, the company may receive proceeds from the...Show More